Schizophrenia and obsessive-compulsive disorder.
Kavi
K
Devulapalli
Henry A
HA
Nasrallah
D014150:Antipsychotic Agents / Q000627:therapeutic use / Q000633:toxicity; D003024:Clozapine / Q000627:therapeutic use / Q000633:toxicity; D015897:Comorbidity; D019388:Cytochrome P-450 CYP1A2; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D016666:Fluvoxamine / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D012307:Risk Factors; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D012565:Schizophrenic Psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use / Q000633:toxicity
D014150:Antipsychotic Agents; D003024:Clozapine; D019388:Cytochrome P-450 CYP1A2; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; C504573:CYP1A2 protein, human; C510163:CYP3A4 protein, human